These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11865159)

  • 1. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules.
    Davit BM; Singh GJ; Conner DP
    Neurology; 2002 Feb; 58(4):666-7; author reply 666-7. PubMed ID: 11865159
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules.
    Wilder BJ; Leppik I; Hietpas TJ; Cloyd JC; Randinitis EJ; Cook J
    Neurology; 2001 Aug; 57(4):582-9. PubMed ID: 11524464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food on the bioavailability of 100-mg dilantin Kapseals.
    Cook J; Randinitis E; Wilder BJ
    Neurology; 2001 Aug; 57(4):698-700. PubMed ID: 11524482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes associated with brand-to-generic phenytoin interchange.
    Kinikar SA; Delate T; Menaker-Wiener CM; Bentley WH
    Ann Pharmacother; 2012 May; 46(5):650-8. PubMed ID: 22550275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic profile of a 300-mg extended phenytoin sodium capsule (Dilantin) formulation.
    Randinitis EJ; Buchanan RA; Kinkel AW
    Epilepsia; 1990; 31(4):458-64. PubMed ID: 2369880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose comparison of the relative bioavailability of phenytoin suspension and extended capsules.
    Fitzsimmons WE; Garnett WR; Comstock TJ; Pellock JM
    Epilepsia; 1986; 27(4):464-8. PubMed ID: 3720707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of phenytoin sodium capsules available in Thailand. Part I: In vitro study.
    Suthisisang C; Payakachat N
    J Med Assoc Thai; 1998 Jan; 81(1):58-63. PubMed ID: 9470323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study.
    Suthisisang C; Payakachat N; Chulavatnatol S; Towanabut S
    J Med Assoc Thai; 1998 Jan; 81(1):64-70. PubMed ID: 9470324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of doses on the bioavailability of phenytoin from a prompt-release and an extended-release preparation: single dose study.
    Rojanasthien N; Chaichana N; Teekachunhatean S; Kumsorn B; Sangdee C; Chankrachang S
    J Med Assoc Thai; 2007 Sep; 90(9):1883-93. PubMed ID: 17957935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dilantin jeopardy: avoiding the dangers of phenytoin.
    Schlicher ML
    Medsurg Nurs; 1998 Dec; 7(6):343-7, 356. PubMed ID: 10036438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenytoin recovery from percutaneous endoscopic gastrostomy Pezzer catheters after long-term in vitro administration.
    Seifert CF; McGoodwin PL; Allen LV
    JPEN J Parenter Enteral Nutr; 1993; 17(4):370-4. PubMed ID: 8271363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.
    Doak KK; Haas CE; Dunnigan KJ; Reiss RA; Reiser JR; Huntress J; Altavela JL
    Pharmacotherapy; 1998; 18(3):637-45. PubMed ID: 9620116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the phenytoin-enteral feeding formula interaction a myth?
    Bertino JS
    Nutr Clin Pract; 1996 Aug; 11(4):175-6. PubMed ID: 9070019
    [No Abstract]   [Full Text] [Related]  

  • 14. No influence of pantoprazole on the pharmacokinetics of phenytoin.
    Middle MV; Müller FO; Schall R; Groenewoud G; Hundt HK; Huber R; Bliesath H; Steinijans VW
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S72-5. PubMed ID: 8793606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget Impact Analysis of Extended-Release Phenytoin Capsules Compared With Immediate-Release Phenytoin Capsules for Patients With Epilepsy in Thailand.
    Tiamkao S; Suthipinijtham P
    Value Health Reg Issues; 2020 May; 21():22-28. PubMed ID: 31634793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of enteral feedings on phenytoin sodium absorption from capsules.
    Nishimura LY; Armstrong EP; Plezia PM; Iacono RP
    Drug Intell Clin Pharm; 1988 Feb; 22(2):130-3. PubMed ID: 3127188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS).
    Atef E; Belmonte AA
    Eur J Pharm Sci; 2008 Nov; 35(4):257-63. PubMed ID: 18706499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of phenytoin sodium suspensions for the treatment of open wounds.
    Rhodes RS; Kuykendall JR; Heyneman CA; May MP; Bhushan A
    Int J Pharm Compd; 2006; 10():74-8. PubMed ID: 23974120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of processing parameters and controlled environment storage on the disproportionation and dissolution of extended-release capsule of phenytoin sodium.
    Rahman Z; Dharani S; Barakh Ali SF; Afrooz H; Reddy IK; Khan MA
    Int J Pharm; 2018 Oct; 550(1-2):290-299. PubMed ID: 30031866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenytoin sodium microcapsules: bench scale formulation, process characterization and release kinetics.
    Yazici E; Oner L; Kaş HS; Hincal AA
    Pharm Dev Technol; 1996 Jul; 1(2):175-83. PubMed ID: 9552344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.